Aprea Therapeutics, Inc. Form 8-K Summary
Reporting date: May 16, 2022. This current report primarily announces Aprea’s completed business combination with Atrin Pharmaceuticals Inc.; it does not provide a quarterly or annual financial update.
Business Context and Transaction
- Aprea completed a two-step merger with Atrin, with Atrin becoming a wholly owned subsidiary and then merging into Aprea’s wholly owned subsidiary, ATR Merger Sub II LLC.
- The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
- Aprea issued 1,117,394 shares of common stock and 2,949,630 shares of Series A Non-Voting Convertible Preferred Stock to Atrin securityholders.
- Each Series A Preferred Stock share is convertible into 10 common shares after stockholder approval, subject to ownership limitations. The preferred shares represent potential issuance of up to 29,496,300 common shares before applicable conversion limitations.
- The common stock continued to trade under the symbol APRE on Nasdaq.
Financial Metrics, Liquidity, and Capitalization
- The filing does not provide clear figures for revenue, net income or loss, cash flow, operating margins, cash, debt, liquidity runway, or other operating financial metrics.
- The transaction was completed through equity issuance; the filing does not disclose cash consideration paid for Atrin.
- Aprea issued the securities in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act and/or Regulation D.
- Aprea agreed to file a resale registration statement for certain Atrin securityholders within 90 days of the Merger Agreement, subject to permitted extensions, and to use reasonable best efforts to have it declared effective within specified periods.
Material Changes Versus the Prior Period
- Aprea acquired Atrin and added Atrin’s development platform and personnel to the combined company.
- Leadership changes include the planned resignation of Christian S. Schade as Chief Executive Officer following the stockholders’ meeting. Oren Gilad was appointed President and is expected to become Chief Executive Officer after that meeting, and Greg Korbel became Chief Operating Officer.
- Fouad Namouni and Michael A. Kelly resigned from the Board. Michael Grissinger, Rif Pamukcu, Oren Gilad and Marc Duey joined the Board, increasing its size from seven to eight directors, with a ninth director expected after the stockholders’ meeting.
- Outstanding board options accelerated in full, and outstanding options and restricted stock units accelerated upon closing, subject to the applicable award terms.
- Several executive transition and severance arrangements were established, including continued compensation and benefits for specified periods.
Governance, Outlook, and Risks
- Aprea intends to seek stockholder approval for conversion of the Series A Preferred Stock, a reverse stock split, ratification of additional director appointments and potential meeting adjournments.
- Aprea notified Nasdaq that it was not compliant with the audit committee composition requirement because of a vacancy. The company stated that it intends to regain compliance within the applicable cure period.
- A CVR agreement is expected to be executed within 30 days after closing. Each holder of Aprea common stock immediately before the merger is expected to receive one non-transferable CVR per share, providing potential cash payments from net proceeds related to dispositions of specified legacy cancer-therapy assets, including APR-246, eprenetapopt and APR-548.
- Future CVR payments are contingent and are not assured. The CVRs will not be registered with the SEC or listed for trading and will be transferable only in limited circumstances.
- Forward-looking statements include projected cash runways, product development plans, stockholder approval, uses of proceeds and potential CVR payments. The filing cautions that these expectations are subject to clinical, regulatory, financing, execution, market and other risks.
- The filing does not itself provide a detailed operating forecast or quantified guidance.
Important Facts for Investors to Verify
- Review the Merger Agreement and Certificate of Designation for the complete economic, conversion, voting and protective provisions.
- Confirm the number of common shares outstanding on a fully diluted basis after conversion of the Series A Preferred Stock and exercise or vesting of equity awards.
- Track stockholder approval of the conversion proposal and any reverse stock split, as well as the timing and effectiveness of the resale registration statement.
- Monitor Aprea’s remediation of the Nasdaq audit committee deficiency and the appointment of the expected ninth director.
- Review subsequent filings for pro forma financial statements, purchase accounting, cash balances, debt, operating runway and any impairment or restructuring charges arising from the transaction.
- Verify execution of the CVR Agreement and assess whether any proceeds from the specified legacy assets are likely to generate CVR payments.